The U.S. Food and Drug Administration (FDA) has granted priority review for the approval of efanesoctocog alfa, with a…
Articles by Marisa Wexler, MS
The European Commission has granted conditional marketing authorization to BioMarin’s one-time gene therapy Roctavian (valoctocogene roxaparvovec) as a treatment…
Treatment with Hemlibra (emicizumab) improved joint health in people with hemophilia A participating in the Phase 3 HAVEN…
Older men with hemophilia report higher rates of anxiety, depression, and diabetes compared with the general U.S. population, a…
Switching to Hemlibra (emicizumab) can add more than $100,000 a year to healthcare costs for people with hemophilia…
The extended half-life replacement therapies Eloctate and Alprolix can be used to effectively manage bleeding during surgery in people with…
A single dose of Freeline Therapeutics’ experimental gene therapy FLT180a increased the levels of factor IX (FIX) — the…
Most people with hemophilia A or B who switched from an approved prophylactic (preventive) therapy regimen to once-monthly…
The first three participants in the B-LIEVE trial all have factor IX (FIX) levels within the normal range more than…
Once-daily preventive treatment with Novo Nordisk’s experimental therapy concizumab significantly reduced bleeding rates in people with both hemophilia A…